Swiss Strategy Aktiengesellschaft is proud to announce the launch of Switzerland's first smoke-free cigarette, NicStic. The Swiss Medicines Institute, "Swissmedic," has evaluated the product and determined that it does not fall under the scope of medicines law. This means that NicStic can be produced and sold on the Swiss market.
The NicStic "cigarette" allows smokers to get nicotine in a cigarette-like way without exposing themselves or others to harmful tobacco smoke. Smoking bans and restrictions are increasing around the world, and the NicStic product offers a solution for nicotine-dependent smokers who face serious physical and psychological problems due to these developments.
The company has completed product development, and series production is scheduled to begin in the fall of this year. NicStic has received an overwhelming response from the market, and the question is not if, but when the product will be launched.
To finance the global market launch, Swiss Strategy Aktiengesellschaft is currently in talks with private and institutional investors, as well as potential licensees in Europe and overseas.
"We are thrilled to be able to offer this innovative product to the Swiss market and beyond," said Marina Krueger, Ph.D., Chief Medical Officer of Swiss Strategy Aktiengesellschaft. "We believe that the NicStic 'cigarette' offers a solution to a growing problem faced by nicotine-dependent smokers around the world."
About Swiss Strategy A.G.
Swiss Strategy A.G. is a Swiss marketing firm. Its role is to promote science-based innovations in the public interest for the economy and society in Switzerland. Swiss Strategy A.G. promotes limited partnerships between motivated scientists and the Swiss marketplace with inspiring patented inventions for successful Swiss start-ups as well as innovative products and services.
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
For more information about NicStic, visit their website at https://nicstic.webnode.com.
Investor Relations:
No comments:
Post a Comment